Standard BioTools Inc.
LAB
$1.07
-$0.045-4.04%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 33.86% | 65.28% | 49.37% | 30.24% | 33.42% |
| Total Other Revenue | -- | -6.02% | 156.55% | 10.17% | -21.80% |
| Total Revenue | 33.86% | 64.03% | 48.23% | 29.25% | 31.27% |
| Cost of Revenue | 54.43% | 76.07% | 222.38% | 124.59% | 48.31% |
| Gross Profit | 7.98% | 47.12% | -24.01% | -31.21% | 14.69% |
| SG&A Expenses | 29.40% | 76.73% | 60.25% | 39.69% | 15.57% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 38.02% | 81.42% | 69.21% | 45.38% | 15.52% |
| Operating Income | -44.12% | -110.75% | -108.11% | -71.63% | 1.78% |
| Income Before Tax | -47.76% | -86.39% | -65.84% | -40.77% | 32.41% |
| Income Tax Expenses | -7.26% | 26.77% | -79.68% | 189.87% | 115.91% |
| Earnings from Continuing Operations | -47.56% | -86.03% | -64.53% | -40.99% | 31.14% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -47.56% | -86.03% | -64.53% | -40.99% | 31.14% |
| EBIT | -44.12% | -110.75% | -108.11% | -71.63% | 1.78% |
| EBITDA | -57.92% | -135.98% | -119.97% | -43.32% | 20.96% |
| EPS Basic | 64.34% | 41.45% | 25.93% | 15.31% | 40.19% |
| Normalized Basic EPS | 58.02% | 54.25% | 37.65% | 26.54% | 51.59% |
| EPS Diluted | 64.68% | 42.04% | 25.77% | 14.40% | 39.74% |
| Normalized Diluted EPS | 58.02% | 54.25% | 37.65% | 26.54% | 51.59% |
| Average Basic Shares Outstanding | 181.50% | 346.12% | 253.34% | 161.12% | 68.66% |
| Average Diluted Shares Outstanding | 181.50% | 346.12% | 253.34% | 161.12% | 68.66% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |